Research programme: influenza virus vaccine - MediVas
Alternative Names: H5N1 vaccine - MediVasLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator MediVas-LLC
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Intranasal)
- 18 Oct 2006 Preclinical trials in Influenza virus infections in USA (Intranasal)